Pirfenidone dose-response in patients with idiopathic pulmonary fibrosis (IPF): A comprehensive analysis of outcomes in CAPACITY 2
U. Costabel, C. Albera, W. Bradford, T. King, P. Noble, S. Sahn, J. Szwarcberg, D. Valeyre, R. du Bois (Essen, Germany; , Italy; Brisbane, San Francisco, Durham, Charleston, Denver, United States Of America; Paris, France)
Source: Annual Congress 2010 - New insights in the treatment of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
U. Costabel, C. Albera, W. Bradford, T. King, P. Noble, S. Sahn, J. Szwarcberg, D. Valeyre, R. du Bois (Essen, Germany; , Italy; Brisbane, San Francisco, Durham, Charleston, Denver, United States Of America; Paris, France). Pirfenidone dose-response in patients with idiopathic pulmonary fibrosis (IPF): A comprehensive analysis of outcomes in CAPACITY 2. Eur Respir J 2010; 36: Suppl. 54, 388
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: